Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rosiglitazone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: Rosiglitazone. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2004-002644-10 Sponsor Protocol Number: CLAF237A2327E1 Start Date*: 2005-01-19
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve pati...
    Medical condition: Diabetes Mellitus II
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000482-35 Sponsor Protocol Number: ARA102198 Start Date*: 2004-10-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arth...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004247-22 Sponsor Protocol Number: RES104033 Start Date*: 2005-06-07
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 28-day, Randomised, Double-Blind, Active Comparator, Controlled Study to Assess the Effects of Rosiglitazone, Inhaled Corticosteroid, Theophylline and Theophylline Plus Inhaled Corticosteroid on ...
    Medical condition: Smokers that are asthmatic
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002407-17 Sponsor Protocol Number: DN 2 Start Date*: Information not available in EudraCT
    Sponsor Name:Technical University Dresden
    Full Title: Effects of rosiglitazone on renal hemodynamics and proteinuria of type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy
    Medical condition: type 2 diabetic patients with proteinuria and chronic renal failure due to overt diabetic nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005045-35 Sponsor Protocol Number: CLAF237A2327 Start Date*: 2005-02-17
    Sponsor Name:Novartis Sverige AB
    Full Title: A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003001-49 Sponsor Protocol Number: P05.020 Start Date*: 2006-08-07
    Sponsor Name:Leiden University Medical Center
    Full Title: Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease
    Medical condition: Chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002243-27 Sponsor Protocol Number: 305/2004 Start Date*: 2004-08-14
    Sponsor Name:Clinical Pharmacology
    Full Title: Vascular effects of peroxisome proliferator–activated receptor gamma stimulation with rosiglitazone during exogenousely elevated free fatty acid concentrations in healthy volunteers
    Medical condition: healthy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003483-59 Sponsor Protocol Number: CVAL489A2429 Start Date*: 2006-12-18
    Sponsor Name:VU University Medical Centre
    Full Title: PRESERVE TRIAL: Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects; A 52-week randomized controlled factorial study in subjects with impaired fasting glucose and/or im...
    Medical condition: subjects with impaired fasting glucose (IFG; blood glucose > or = 5.6 and < 7 mmol/l) and/or impaired glucose tolerance (IGT; 2-h post-load glucose 7.8-11.1 mmol/l).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018429 Glucose tolerance impaired LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005089-34 Sponsor Protocol Number: BRL-049653/461 Start Date*: 2006-09-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A double-blind, randomised, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilisation and cognition in subjects...
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005030-73 Sponsor Protocol Number: AVD111960 Start Date*: 2009-11-11
    Sponsor Name:GlaxoSmithKline
    Full Title: Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In Peopl...
    Medical condition: - Incidence of CV outcomes compared to placebo for the TZD class as a whole, rosiglitazone (RSG), and pioglitazone (PIO) when added to the therapeutic regimen of a person with type 2 diabetes who h...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Prematurely Ended) NL (Completed) DE (Completed) DK (Prematurely Ended) SK (Prematurely Ended) FR (Prematurely Ended) LV (Prematurely Ended) IE (Completed) IT (Prematurely Ended) FI (Completed) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006060-63 Sponsor Protocol Number: C LF23-0121 05 01 Start Date*: 2006-06-22
    Sponsor Name:FOURNIER Laboratories Ireland Ltd
    Full Title: A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia
    Medical condition: Patients with type 2 diabetes mellitus and dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002516-85 Sponsor Protocol Number: 01-2011 Start Date*: 2011-10-20
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Open-label study to evaluate the efficacy and tolerability of orally administered rosiglitazone in patients with progressive bone Fibrodysplasia (FOP)
    Medical condition: Fibrodysplasia Ossificans Progressive (FOP) is a rare genetically based disability, characterized by progressive heterotopic ossification, usually associated with congenital malformation of the toes.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028393 Musculoskeletal and connective tissue disorders NEC HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001402-92 Sponsor Protocol Number: AVA102670 Start Date*: 2006-09-06
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) BE (Completed) CZ (Completed) SI (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004714-14 Sponsor Protocol Number: 2007-223 Start Date*: 2007-10-25
    Sponsor Name:Aarhus University Hospital, Aarhus Sygehus
    Full Title: The effect of glitazone-treatment on bone turn-over and bone marrow cells
    Medical condition: We want to investigate if rosiglitazone treatment can induce bone loss in humans
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031289 Osteoporosis, unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000985-12 Sponsor Protocol Number: AVA100468 Start Date*: 2004-08-03
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.
    Medical condition: Mild to moderate Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001240-30 Sponsor Protocol Number: CL3-05702-013 Start Date*: 2006-10-31
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year in...
    Medical condition: Diabetes mellitus non insulino dependant
    Disease: Version SOC Term Classification Code Term Level
    9.0 10027433 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) LV (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) HU (Completed) SI (Prematurely Ended) AT (Prematurely Ended) GB (Completed) SK (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000013-36 Sponsor Protocol Number: 49653/416 Start Date*: 2005-08-17
    Sponsor Name:Dr. Olivier F. Bertrand , Laval Hospital
    Full Title: A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression after Coronary Bypass Surgery in Diabetic Patients
    Medical condition: Atherosclerosis progression in vein grafts in diabetic patients after coronary bypass surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002488-20 Sponsor Protocol Number: mk 431 prot 052 Start Date*: 2006-06-15
    Sponsor Name:MERCK SHARP DOHME
    Full Title: Studio Multicentrico randomizzato in doppio cieco per valutare la sicurezza e l'efficacia dell'aggiunta di sitagliptin MK 0431 in pazienti affetti da diabete mellito di tipo 2 in trattamento con me...
    Medical condition: diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004152-20 Sponsor Protocol Number: AVA 102675 Start Date*: 2007-11-16
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-t...
    Medical condition: Mild-moderate Alzheimer disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012271 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Prematurely Ended) BE (Completed) ES (Completed) GR (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005078-28 Sponsor Protocol Number: AVA102677 Start Date*: 2007-11-28
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5).
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) EE (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:38:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA